Navigation Links
Skin Cells Make Use of Geographic Co-Ordinates to Reach Their Destination

Scientists at the Stanford University have discovered that skin cells make use of the three geographic coordinates: latitude// , longitude and altitude to reach their destined place in the body.

Researchers also think that this plays an important role in directing the embryonic and non differentiated cells. ‘There is a logic to the body that we didn't understand before,’ said John Rinn, PhD, a postdoctoral scholar in the laboratory of Howard Chang, MD, PhD, assistant professor of dermatology. ‘Our skin is actively maintaining itself throughout our life, and these 'address codes' help the cells know how to respond appropriately.’ Rinn is the first author of the research, which is published in the current issue of Public Library of Science-Genetics. Until now it's been a mystery as to how adult skin, which consists of basically the same components all over the body, knows to grow hair in some areas like the scalp, while manufacturing sweat glands, calluses and fingerprint whorls in others.

In 1969, well-known developmental biologist Lewis Wolpert authored a famous treatise that described two possible ways for cells to know where they are in the body: Either they infer their location and adjust their behavior based on interactions with nearby cells, or they deduce their ‘positional identity’ through the use of some type of coordinate system. The findings from the new Stanford study bolster the second possibility. The scientists analyzed the gene-expression profiles of adult fibroblasts from more than 40 areas of the body. They found about 400 genes whose expression patterns varied with the cells' original location. Those from the top half of the body - arms, head and chest, for example - shared expression patterns that were markedly different from the patterns shared among cells from the bottom part of the body, such as the legs and feet.

Similar patterns existed among cells originating close to or far from the center of the body, and tho
'"/>




Page: 1 2 3

Related medicine news :

1. Blood Cells Capable of Regenerating Liver
2. White Cells Count Can Predict Heart Attack Death Risk
3. Gene Therapy Destroys Pancreatic Cancer Cells
4. Stem Cells Have Few Mutations
5. Heart may pull Cells from Body to Self-repair
6. Cells critical for asthma development found
7. Vitamin D Wipes out Cancer Cells
8. Bone Marrow Cells Help Heart Attack Patients
9. Islet Cells May Lead to Diabetes CureChildren
10. Stem Cells Found To Offer Promise For Hair Growth
11. Bone Marrow Cells Could Yield A New Lease of Life
Post Your Comments:
Breaking Medicine Technology:Heska Announces Extension of Credit Agreement With Wells Fargo 2Heska Announces Extension of Credit Agreement With Wells Fargo 3Anesiva Completes Sale of its Zingo(TM) Assets to Powder Pharmaceuticals and Lee's Pharmaceuticals 2St. Luke's Hospital Acquires Pioneering Technology From BrainLAB 2St. Luke's Hospital Acquires Pioneering Technology From BrainLAB 3Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 1Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 2Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 3Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 4Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 5Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 6Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 7Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 8Sanofi aventis and Merrimack Pharmaceuticals Enter Into a Worldwide Collaboration and Licensing Agreement on MM 121 an Anti ErbB3 Monoclonal Antibody 5122 9Golden Meditech Announces HK 24217 Million Private Equity Financing for Hospital Subsidiary 14309 1Golden Meditech Announces HK 24217 Million Private Equity Financing for Hospital Subsidiary 14309 2Method to Identify Female Athletes at a High Risk for Knee Injury Discovered 58628 1Method to Identify Female Athletes at a High Risk for Knee Injury Discovered 58628 2